European Psychiatry - Volume 33

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S12–S13

S13

patients. Other compounds such as naltrexone showed similar

effects in smaller trials but are not approved for reduction. More

studies testing further compounds are underway.

Conclusions

This new approach has the potential to lower the

barriers which to date prevent many patients from accepting

treatment for their alcohol problems. Two research questions war-

rant further study: (1) does the reduction in alcohol consumption

translate into health and other benefits, and (2) are there specific

subgroups of patients who benefit more than others. Preliminary

answers will be given in the lecture.

Disclosure of interest

The author has not supplied his declaration

of competing interest.